Epidural plus general anesthesia may cut muscle relaxant use in stomach cancer surgery
NCT ID NCT05907811
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 60 people having stomach cancer surgery to see if adding an epidural to general anesthesia changes how much muscle relaxant is needed and how fast it wears off. Half got general anesthesia alone, half got general anesthesia plus a thoracic epidural. Researchers measured muscle recovery time and pain levels. The goal was to find the best way to manage anesthesia for these surgeries.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neuromuscular blocker (rocuronium)
What this could lead to
If successful, this could help anesthesiologists choose the best anesthesia method to reduce muscle relaxant use and improve recovery after gastric cancer surgery.
What could go wrong
This is a small, single-center study with only 60 patients. Results may not apply to other surgeries or hospitals. The study is already completed, so no new treatments are being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arzu Esen Tekeli
Van, Turkey, 65100, Turkey (Türkiye)